Romidepsin: Evidence for its potential use to manage previously treated cutaneous T cell lymphoma

Core Evidence

Volumn 6, Issue , 2011, Pages 1-12

  Poligone, Brian ^a   Lin, Janet ^a   Chung, Catherine ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Cutaneous T cell lymphoma; Histone deacetylase inhibitor; Mycosis fungoides; Romidepsin; S zary syndrome; Treatment

Indexed keywords

HISTONE DEACETYLASE; ROMIDEPSIN;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; CELL CYCLE ARREST; CUTANEOUS T CELL LYMPHOMA; DYSGEUSIA; ELECTROCARDIOGRAM; FATIGUE; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; NAUSEA; NONHUMAN; QT PROLONGATION; REVIEW; SCORING SYSTEM; ST SEGMENT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 84865378954     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S9084     Document Type: Review

References (32)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
2. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3884 cases. Blood. 2009;113(21):5064-5073.
3. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007;143(7): 854-859.
4. Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev. 2007;33(2):146-160.
5. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-1722.
6. Wieselthier JS, Koh HK. Sezary syndrome: Diagnosis, prognosis, and critical review of treatment options. J Am Acad Dermatol. 1990;22(3): 381-401.
7. Gardner JM, Evans KG, Musiek A, Rook AH, Kim EJ. Update on treatment of cutaneous T-cell lymphoma. Curr Opin Oncol. 2009;21(2): 131-137.
8. Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321(26):1784-1790.
9. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9(5):1089-1107.
10. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137(5):581-593.
11. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109-3115.
12. Foss F. Mycosis fungoides and the Sezary syndrome. Curr Opin Oncol. 2004;16(5):421-428.
13. Lansigan F, Choi J, Foss FM. Cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2008;22(5):979-996.
14. Zelenetz AD, Advani RH, Byrd JC, et al. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2008;6(4):356-421.
15. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Longterm outcome of 525 patients with mycosis fungoides and Sezary syndrome: Clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857-866.
16. Konstantinopoulos PA, Vandoros GP, Papavassiliou AG. FK228 (depsipeptide): A HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother Pharmacol. 2006;58(5):711-715.
17. Richon VM, O'Brien JP. Histone deacetylase inhibitors: A new class of potential therapeutic agents for cancer treatment. Clin Cancer Res. 2002;8(3):662-664.
18. Ueda H, Nakajima H, Hori Y, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo). 1994;47(3):301-310.
19. Shigematsu N, Ueda H, Takase S, Tanaka H, Yamamoto K, Tada T. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination. J Antibiot (Tokyo). 1994;47(3):311-314.
20. Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: Mechanisms and potential clinical implications. Clin Cancer Res. 2009;15(12):3947-3957.
21. Glaser KB. HDAC inhibitors: Clinical update and mechanism-based potential. Biochem Pharmacol. 2007;74(5):659-671.
22. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 2009;15(12):3958-3969.
23. Peart MJ, Tainton KM, Ruefli AA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2003;63(15): 4460-4471.
24. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002;8(3):718-728.
25. Bates SE, Zhan Z, Steadman K, et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol. 2010;148(2):256-267.
26. Keefe DL. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: Is there cause for concern? Oncologist. 2002;7(1): 65-72.
27. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report. Blood. 2001;98(9):2865-2868.
28. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32): 5410-5417.
29. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485-4491.
30. Woo S, Gardner ER, Chen X, et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009;15(4): 1496-1503.
31. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12(12):3762-3773.
32. Molife R, Fong P, Scurr M, Judson I, Kaye S, de Bono J. HDAC inhibitors and cardiac safety. Clin Cancer Res. 2007;13(3):1068; author reply 1068-1069.